CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:
Cell & Gene Meeting on the Mesa
Panel: What does the future hold for gene editing?
Date: Friday, October 4, 2019
Time: 9:45 a.m. PT
Chardan 3rd Annual Genetic Medicines Conference
Date: Monday, October 7, 2019
Fireside Chat
Time: 10:30 a.m. ET
Panel: What’s next in gene editing technologies?
Time: 12:45 p.m. ET
Location: New York, NY
The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Investors
Mark
Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com